Skip to main content
Top
Published in: Tumor Biology 5/2010

01-10-2010 | Research Article

The role of NF-κB and PPARγ in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors

Authors: Vivek Vaish, Lalita Tanwar, Sankar Nath Sanyal

Published in: Tumor Biology | Issue 5/2010

Login to get access

Abstract

Initiation of malignancy is dependent upon the basic ratio of cell proliferation and apoptosis. Many molecular proteins and pathways are responsible for the imbalance of proliferation and apoptosis ratio. For example, Akt is a key biomolecule which regulates the cell survival signals via various downstream pathways. One of those pathways is nuclear factor-κB activation which also regulates many downstream pathways that are essential for cell survival. Along with these anti-apoptotic pathways, cells do have a parallel mechanism to prevent malignancy with the help of the ligand-induced nuclear receptors, e.g., peroxisome proliferator-activated receptor gamma (PPARγ). PPARγ has been found to be expressed in many cancer cell types and reported to be a pro-apoptotic transcription factor. The study aimed to observe the ability of two cyclooxygenase-dependent non-steroidal anti-inflammatory drugs (NSAIDs) in the prevention of experimentally induced early neoplasm of colon via NF-κB and PPARγ pathways. Early stages of colorectal cancer were produced in rats with 1,2-dimethylhydrazine dihydrochloride. Western blotting and immunohistochemistry were performed along with morphological and histological analysis. According to the expression levels of NF-κB and PPARγ in the cell nuclei, it is observed that NSAIDs may prevent colorectal cancer in the early stages by a concomitant down-regulation of NF-κB and up-regulation of PPARγ. COX-independent mechanism of anti-carcinogenesis was observed by COX-dependent NSAIDs in colorectal cancer.
Literature
1.
go back to reference Hwang DH, Fung V, Dannenberg AJ. National Cancer Institute Workshop on Chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. Neoplasia. 2002;4:91–7. doi:10.1038/sj/neo/7900226.CrossRefPubMed Hwang DH, Fung V, Dannenberg AJ. National Cancer Institute Workshop on Chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. Neoplasia. 2002;4:91–7. doi:10.​1038/​sj/​neo/​7900226.CrossRefPubMed
2.
go back to reference Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, et al. Cyclooxygenase in biology and disease. Faseb J. 1998;12:1063–73.PubMed Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, et al. Cyclooxygenase in biology and disease. Faseb J. 1998;12:1063–73.PubMed
3.
go back to reference Wang D, Wang H, Shi Q, Katkuri S, et al. Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ. Cancer Cell. 2004;6:285–95.CrossRefPubMed Wang D, Wang H, Shi Q, Katkuri S, et al. Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ. Cancer Cell. 2004;6:285–95.CrossRefPubMed
4.
go back to reference Tsujii M, Kawano S, Dubois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA. 1997;94:3336–40.CrossRefPubMed Tsujii M, Kawano S, Dubois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA. 1997;94:3336–40.CrossRefPubMed
5.
go back to reference Vandoros GP, Konstantinopoulos PA, et al. PPAR-gamma is expressed and NF-κB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol. 2006;132:76–84. doi:10.1007/s00432-005-0042-z.CrossRefPubMed Vandoros GP, Konstantinopoulos PA, et al. PPAR-gamma is expressed and NF-κB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol. 2006;132:76–84. doi:10.​1007/​s00432-005-0042-z.CrossRefPubMed
6.
go back to reference Benitah SA, Valerón PF, Lacal JC. ROCK and nuclear factor-κB-dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences. Mol Biol Cell. 2003;14:3041–54. doi:10.1091/mbc.E03-01-0016.CrossRefPubMed Benitah SA, Valerón PF, Lacal JC. ROCK and nuclear factor-κB-dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences. Mol Biol Cell. 2003;14:3041–54. doi:10.​1091/​mbc.​E03-01-0016.CrossRefPubMed
8.
go back to reference Peng Y, Power MR, Li B, Lin TJ. Inhibition of IKK down-regulates antigen + IgE-induced TNF production by mast cells: a role for the IKK-IκB-NF-κB pathway in IgE-dependent mast cell activation. J Leukoc Biol. 2005;77:975–83. doi:10.1189/jlb.0204115.CrossRefPubMed Peng Y, Power MR, Li B, Lin TJ. Inhibition of IKK down-regulates antigen + IgE-induced TNF production by mast cells: a role for the IKK-IκB-NF-κB pathway in IgE-dependent mast cell activation. J Leukoc Biol. 2005;77:975–83. doi:10.​1189/​jlb.​0204115.CrossRefPubMed
9.
10.
go back to reference Madrid LV, Wang CY, Guttridge DC, et al. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kB. Mol Cell Biol. 2000;20:1626–38.CrossRefPubMed Madrid LV, Wang CY, Guttridge DC, et al. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kB. Mol Cell Biol. 2000;20:1626–38.CrossRefPubMed
11.
go back to reference Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. Faseb J. 2001;15:2057–72.CrossRefPubMed Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. Faseb J. 2001;15:2057–72.CrossRefPubMed
13.
go back to reference Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with Celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res. 2002;62:165–70.PubMed Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with Celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res. 2002;62:165–70.PubMed
14.
go back to reference Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMed Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMed
15.
go back to reference Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252–66.PubMed Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252–66.PubMed
17.
go back to reference Takeda H, Sonoshita M, Oshima H, et al. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res. 2003;63:4872–7.PubMed Takeda H, Sonoshita M, Oshima H, et al. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res. 2003;63:4872–7.PubMed
18.
go back to reference Hirose Y, Kuno T, Yamada Y, et al. Azoxymethane-induced beta-catenin-accumulated crypts in colonic mucosa of rodents as an intermediate biomarker for colon carcinogenesis. Carcinogenesis. 2003;24:107–11.CrossRefPubMed Hirose Y, Kuno T, Yamada Y, et al. Azoxymethane-induced beta-catenin-accumulated crypts in colonic mucosa of rodents as an intermediate biomarker for colon carcinogenesis. Carcinogenesis. 2003;24:107–11.CrossRefPubMed
19.
go back to reference Ochiai M, Ushigome M, Fujiwara K, et al. Characterization of dysplastic aberrant crypt foci in the rat colon induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Am J Pathol. 2003;163:1607–14.PubMed Ochiai M, Ushigome M, Fujiwara K, et al. Characterization of dysplastic aberrant crypt foci in the rat colon induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Am J Pathol. 2003;163:1607–14.PubMed
20.
go back to reference Rodrigues MAM, Silva LAG, Salvadori DMF, et al. Aberrant crypt foci and colon cancer: comparison between a short- and medium-term bioassay for colon carcinogenesis using dimethylhydrazine in Wistar rats. Braz J Med Biol Res. 2002;35:351–5.PubMed Rodrigues MAM, Silva LAG, Salvadori DMF, et al. Aberrant crypt foci and colon cancer: comparison between a short- and medium-term bioassay for colon carcinogenesis using dimethylhydrazine in Wistar rats. Braz J Med Biol Res. 2002;35:351–5.PubMed
21.
go back to reference Roy HK, Olusola BF, Clemens DL, Karolski WJ, et al. Akt proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis. 2002;23:201–5.CrossRefPubMed Roy HK, Olusola BF, Clemens DL, Karolski WJ, et al. Akt proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis. 2002;23:201–5.CrossRefPubMed
22.
go back to reference Itoh N, Semba S, Ito M, Takeda H, et al. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer. 2002;94:3127–34. doi:10.1002/cncr.10591.CrossRefPubMed Itoh N, Semba S, Ito M, Takeda H, et al. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer. 2002;94:3127–34. doi:10.​1002/​cncr.​10591.CrossRefPubMed
24.
go back to reference Chang F, Lee JT, Navolanic PM, Steelman LS, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17:590–603. doi:10.1038/sj.leu.2402824.CrossRefPubMed Chang F, Lee JT, Navolanic PM, Steelman LS, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17:590–603. doi:10.​1038/​sj.​leu.​2402824.CrossRefPubMed
26.
go back to reference St-Germain ME, Gagnon V, Parent S, Asselin E. Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-κB/IκB pathway. Mol Cancer. 2004;3:1–11.CrossRef St-Germain ME, Gagnon V, Parent S, Asselin E. Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-κB/IκB pathway. Mol Cancer. 2004;3:1–11.CrossRef
28.
go back to reference Song ZJ, Gong P, Wu YE. Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. World J Gastroenterol. 2002;8:591–5.PubMed Song ZJ, Gong P, Wu YE. Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. World J Gastroenterol. 2002;8:591–5.PubMed
29.
30.
go back to reference Smulson ME, Pang D, Jung M, Dimtchev A, et al. Irreversible binding of poly(ADP)ribose polymerase cleavage product to DNA ends revealed by atomic force microscopy: possible role in apoptosis. Cancer Res. 1998;58:3495–8.PubMed Smulson ME, Pang D, Jung M, Dimtchev A, et al. Irreversible binding of poly(ADP)ribose polymerase cleavage product to DNA ends revealed by atomic force microscopy: possible role in apoptosis. Cancer Res. 1998;58:3495–8.PubMed
31.
go back to reference Pétrilli V, Herceg Z, Hassa PO, Patel NSA, et al. Noncleavable poly(ADP-ribose)polymerase-1 regulates the inflammation response in mice. J Clin Invest. 2004;114:1072–81. doi:10.1172/JCI200421854.PubMed Pétrilli V, Herceg Z, Hassa PO, Patel NSA, et al. Noncleavable poly(ADP-ribose)polymerase-1 regulates the inflammation response in mice. J Clin Invest. 2004;114:1072–81. doi:10.​1172/​JCI200421854.PubMed
32.
go back to reference Takada I, Suzawa M, Kato S. Nuclear receptors as targets for drug development: crosstalk between peroxisome proliferator-activated receptor γ and cytokines in bone marrow-derived mesenchymal stem cells. J Pharmacol Sci. 2005;97:184–9.CrossRefPubMed Takada I, Suzawa M, Kato S. Nuclear receptors as targets for drug development: crosstalk between peroxisome proliferator-activated receptor γ and cytokines in bone marrow-derived mesenchymal stem cells. J Pharmacol Sci. 2005;97:184–9.CrossRefPubMed
33.
35.
go back to reference Barrera G, Toaldo C, Pizzimenti S, Cerbone A, et al. The role of PPAR ligands in controlling growth-related gene expression and their interaction with lipoperoxidation products. PPAR Res. 2008;2008:524671. doi:10.1155/2008/524671.PubMed Barrera G, Toaldo C, Pizzimenti S, Cerbone A, et al. The role of PPAR ligands in controlling growth-related gene expression and their interaction with lipoperoxidation products. PPAR Res. 2008;2008:524671. doi:10.​1155/​2008/​524671.PubMed
Metadata
Title
The role of NF-κB and PPARγ in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors
Authors
Vivek Vaish
Lalita Tanwar
Sankar Nath Sanyal
Publication date
01-10-2010
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2010
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0051-7

Other articles of this Issue 5/2010

Tumor Biology 5/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine